Načítá se...
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
BACKGROUND: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop wi...
Uloženo v:
| Vydáno v: | BMC Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7216404/ https://ncbi.nlm.nih.gov/pubmed/32397977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06920-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|